Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow Growth (1y) (2018 - 2026)
Kiniksa Pharmaceuticals International (KNSA) Net Cash Flow Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.33 Bn | 87.46 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.86 Bn | 32.12 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.54 Bn | 30.60 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 23.12 Bn | 20.96 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | -1,020.00% |
| 10 | Kiniksa Pharmaceuticals International | 4.87 Bn | 4.40 Bn | 193.47 Mn | 192.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 192.09% |
| Dec 31, 2025 | -110.74% |
| Sep 30, 2025 | -806.54% |
| Jun 30, 2025 | 183.49% |
| Mar 31, 2025 | -179.85% |
| Dec 31, 2024 | 973.05% |
| Sep 30, 2024 | -136.02% |
| Jun 30, 2024 | -230.86% |
| Mar 31, 2024 | 178.68% |
| Dec 31, 2023 | 81.39% |
| Sep 30, 2023 | -93.54% |
| Jun 30, 2023 | 3.12% |
| Mar 31, 2023 | 28.83% |
| Dec 31, 2022 | 21.66% |
| Sep 30, 2022 | 269.91% |
| Jun 30, 2022 | -35.58% |
| Mar 31, 2022 | -1,116.60% |
| Dec 31, 2021 | -340.42% |
| Sep 30, 2021 | 158.59% |
| Jun 30, 2021 | 180.94% |